Medicomp Inc
$19.9K 746 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Virtus Pharmaceuticals LLC
Virtus Pharmaceuticals LLC reported $19,750.15 across General Payments, Research, and Ownership to 987 physicians and teaching hospitals across 987 transactions.
- $19.8K
- All-tracks total
- 987
- Transactions
- 987
- Recipients
- +$8.6K
- General Payments vs PY2023
Virtus Pharmaceuticals LLC reported $19,750.15 across all CMS Open Payments tracks (General + Research + Ownership) to 987 physicians and teaching hospitals in Program Year 2024 - ranking #1537 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $19,750.15, averaging $20.01 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer virtus-pharmaceuticals-llc Virtus Pharmaceuticals LLC
$19.8K · #1537/1,925 · 0.0% industry · PY2024
- TOT $19.8K
- RANK #1537
- SHARE 0.0%
- TXN 987
- RCP 987
- CAT 1
- GEN $19.8K
- ΔGEN +$8.6K
- TOP1 1.7%
- PY 2024
Volume peers
Nearest volume peer: Medicomp Inc ($19.9K)
Virtus Pharmaceuticals LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Virtus Pharmaceuticals LLC's CMS-reported General Payments increased by $8.6K (+77.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: VIRTUS PHARMACEUTICALS LLCPY2023: VIRTUS PHARMACEUTICALS LLCPY2024: Virtus Pharmaceuticals LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $11,140.37
- PY2024
- $19,750.15
What the Data Shows for Virtus Pharmaceuticals LLC
Virtus Pharmaceuticals LLC ranks #1537 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $19,750.15 across 987 transactions to 987 physicians and teaching hospitals - $20.01 per transaction and $20.01 per recipient on average.
The 1-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $19.8K, accounting for 100.0% of this company's General Payments and 987 transactions.
General Payment Breakdown by Type
Virtus Pharmaceuticals LLC made 1 types of general payments. "Food and Beverage" is the largest category at $19.8K, 100.0% of General Payments.
How Virtus Pharmaceuticals LLC divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $19.8K | 987 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,342.40 (6.8%) of $19,750.15 in this company's General Payments records across 361 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Virtus Pharmaceuticals LLC
The five named recipients with the highest reported General Payments from this company
- 1
George C Perdikis
$327.90 across 13 reported transactions
- 2
Eric Kei Batangan
$269.33 across 9 reported transactions
- 3
James Fleming
$255.28 across 8 reported transactions
- 4
Erin J Henderson
$255.22 across 8 reported transactions
- 5
Paul Kramm
$234.67 across 14 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Virtus Pharmaceuticals LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Virtus Pharmaceuticals LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Virtus Pharmaceuticals LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Gentleman Orthopedic Solutions
$20.0K 136 recipients
Compare payment profiles
Belluscura LLC
$20.0K 1 recipients
Compare payment profiles
OTU Medical Inc.
$20.0K 2 recipients
Compare payment profiles
Core Surgical Group
$20.0K 164 recipients
Compare payment profiles
DentalEZ, Inc.
$20.1K 39 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.